BGM Group Ltd.

BGMNASDAQHealthcare● Active

$0.30

+$0.01(+2.51%)

Market Cap$59845950

P/E Ratio—

52W High$17.17

52W Low$0.256

Avg Volume336K

Open$0.29

Beta1.82

PE Ratio Market Cap Forecast

BGM Group Ltd. (BGM) PE Ratio — Current & Historical Data

Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.

bgm · pe ratio · data through Sep 30, 2024

Core PE Ratio Metrics

Trailing 12 months · TTM

The price-to-earnings (P/E) ratio for BGM Group Ltd. (BGM) measures how much investors pay for each dollar of the company's trailing earnings. BGM's current PE ratio of N/A is calculated by dividing its stock price of $0.30 by its TTM earnings per share of -$0.20.

N/A

P/E Ratio (TTM)N/A — Company is not profitable (TTM)

Source: FMP · /ratios-ttm · /analyst-estimates · 2024-09-30

Forward P/E

N/A

—

EPS (TTM)

-$0.20

TTM · diluted EPS

PEG Ratio

-0.01

▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · BGM Group Ltd. SEC 10-K & 10-Q filings · US GAAPUpdated: 2026-06-08

PE Ratio History

2017 – 2024 · Annual

PE Ratio (TTM)

5Y Avg 14.2x

EPS (Annual)

▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)

Historical PE Range

Past 6 fiscal years · Front-end computed

Average

16.4x

6-yr mean

Median

9.7x

6-yr midpoint

Minimum

7.2x

Lowest year

Maximum

36.9x

Highest year

7.2x
MinQ1 · 25%9.7x
MedianQ3 · 75%36.9x
Max

Historically Low

At N/A, BGM's current P/E is lower than in 0% of its annual fiscal year readings over the past 6 years — historically low.

0th percentileHigher than 0 of 6 historical fiscal year readings

Percentile calculated from annual fiscal year data points, not by trading day. Years where PE ≤ 0 or > 9,999 are excluded.

PE Ratio vs Peers

Drug Manufacturers - Specialty & Generic · 6 peers · Annual PE

Company	Market Cap	PE (Annual)	vs Avg	EPS (TTM)
BGM Group Ltd.You BGM	$60M	N/A	—	-$0.20
ANI Pharmaceuticals, Inc. ANIP	$1.8B	20.21x	—	$3.91
Avadel Pharmaceuticals plc AVDL	$2.1B	N/A	—	-$0.51
Clover Health Investments, Corp. CLOV	$2.0B	N/A	—	-$0.17
Edgewise Therapeutics, Inc. EWTX	$3.8B	N/A	—	-$1.63
Structure Therapeutics Inc. GPCR	$2.1B	N/A	—	-$2.39
Mesoblast Limited MESO	$1.8B	N/A	—	-$0.85

* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio

Annual PE Ratio History

Showing 8 of 8 years

Fiscal Year End	PE Ratio	EPS (TTM)	YoY Change
2024-09-30Latest FY2024	—	$-0.20	—
2023-09-30 FY2023	—	$-1.08	—
2022-09-30 FY2022	36.91x	$0.15	+210.4%
2021-09-30 FY2021	11.89x	$0.46	+56.4%
2020-09-30 FY2020	7.60x	$0.72	+5.3%
2019-09-30 FY2019	7.22x	$0.76	-3.1%
2018-09-30 FY2018	7.45x	$0.74	-72.6%
2017-09-30 FY2017	27.21x	$0.20	—

▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API

About PE Ratio & Methodology

PE Ratio = Stock Price ÷ EPS (TTM)

= $0.30 ÷ -$0.20 = N/A

TTMTrailing Twelve Months — sum of the most recent 4 quarterly EPS figures

Forward PEStock price ÷ analyst consensus EPS estimate for the next fiscal year

PEGPE ÷ earnings growth rate — values below 1.0 suggest growth may justify the premium

Figures tie to SEC 10-K/10-Q and FMP ratio endpoints where noted.

Price history Financial statements Earnings

Frequently asked questions

BGM pe ratio · 6 questions

BGM's current PE ratio is N/A as of 2026-06-08, based on a stock price of $0.30 and TTM EPS of -$0.20. Data sourced from Financial Modeling Prep via BGM's SEC 10-K and 10-Q filings.

BGM PE ratioWhat is BGM PE ratioCurrent PE ratio of BGMBGM PE ratio today

▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · BGM Group Ltd. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-08